Sharon Townson
Chief Tech/Sci/R&D Officer at MONTE ROSA THERAPEUTICS, INC.
Profile
Sharon Townson is currently the Chief Technology Officer at Monte Rosa Therapeutics, Inc. She previously worked as the Scientific Director-Physical Biochemistry at Warp Drive Bio, Inc. from 2016 to 2018 and as the Executive Director & Head-Platform Biology at Kymera Therapeutics, Inc. from 2019 to 2020.
Dr. Townson obtained her undergraduate degree from the University of Salford and her doctorate degree from the University of Manchester Institute of Science & Technology.
Sharon Townson active positions
Companies | Position | Start |
---|---|---|
MONTE ROSA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-12-31 |
Former positions of Sharon Townson
Companies | Position | End |
---|---|---|
KYMERA THERAPEUTICS, INC. | Director/Board Member | 2020-05-31 |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Corporate Officer/Principal | 2018-11-30 |
Training of Sharon Townson
University of Salford | Undergraduate Degree |
University of Manchester Institute of Science & Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
KYMERA THERAPEUTICS, INC. | Health Technology |
MONTE ROSA THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Commercial Services |
- Stock Market
- Insiders
- Sharon Townson